Taratamab

Phase II DeLLphi-301 Study Reveals Impressive Antitumor Activity of Amgen’s First-in-Class Bispecific Antibody Tarlatamab (ESMO 2023)

ESMO 2023: LBA92 Most SCLC patients are diagnosed with cancer that has already spread beyond the lungs, and their average ...